Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Time from autologous to allogeneic hematopoietic stem cell transplantation impacts post-transplant outcomes in multiple myeloma.

Fiorenza S, Routledge D, Collins J, Shipton M, Harrison S, Bajel A, Cavet J, Tholouli E, Gauthier J, Ritchie D.

Bone Marrow Transplant. 2019 Sep 3. doi: 10.1038/s41409-019-0642-x. [Epub ahead of print] No abstract available.

PMID:
31481801
2.

Allogeneic Stem Cell Transplantation for Blast Crisis Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: A Retrospective Study by the EBMT Chronic Malignancies Working Party.

Radujkovic A, Dietrich S, Blok HJ, Nagler A, Ayuk F, Finke J, Tischer J, Mayer J, Koc Y, Sorà F, Passweg J, Byrne JL, Jindra P, Veelken JH, Socié G, Maertens J, Schaap N, Stadler M, Itälä-Remes M, Tholouli E, Arat M, Rocha V, Ljungman P, Yakoub-Agha I, Kröger N, Chalandon Y.

Biol Blood Marrow Transplant. 2019 Oct;25(10):2008-2016. doi: 10.1016/j.bbmt.2019.06.028. Epub 2019 Jul 1.

PMID:
31271884
3.

Patient-Reported Outcome Results From the Open-Label, Randomized Phase III Myeloma X Trial Evaluating Salvage Autologous Stem-Cell Transplantation in Relapsed Multiple Myeloma.

Ahmedzai SH, Snowden JA, Ashcroft AJ, Cairns DA, Williams C, Hockaday A, Cavenagh JD, Ademokun D, Tholouli E, Allotey D, Dhanapal V, Jenner M, Yong K, Cavet J, Hunter H, Bird JM, Pratt G, Parrish C, Brown JM, Morris TCM, Cook G; National Cancer Research Institute Haemato-Oncology Clinical Studies Group.

J Clin Oncol. 2019 Jul 1;37(19):1617-1628. doi: 10.1200/JCO.18.01006. Epub 2019 Apr 10.

4.

The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long-term follow-up results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.

Cook G, Royle KL, O'Connor S, Cairns DA, Ashcroft AJ, Williams CD, Hockaday A, Cavenagh JD, Snowden JA, Ademokun D, Tholouli E, Andrews VE, Jenner M, Parrish C, Yong K, Cavet J, Hunter H, Bird JM, Pratt G, Drayson MT, Brown JM, Morris TCM; National Cancer Research Institute Haemato-oncology Clinical Studies Group.

Br J Haematol. 2019 May;185(3):450-467. doi: 10.1111/bjh.15782. Epub 2019 Feb 6.

5.

Mesenchymal stromal cells for acute graft-versus-host disease: response at 1 week predicts probability of survival.

Galleu A, Milojkovic D, Deplano S, Szydlo R, Loaiza S, Wynn R, Marks DI, Richardson D, Orchard K, Kanfer E, Tholouli E, Saif M, Sivaprakasam P, Lawson S, Bloor A, Pagliuca A, Potter V, Mehra V, Snowden JA, Vora A, Kishore B, Hunter H, Apperley JF, Dazzi F.

Br J Haematol. 2019 Apr;185(1):89-92. doi: 10.1111/bjh.15749. Epub 2019 Jan 13.

6.

ASP2215 in the treatment of relapsed/refractory acute myeloid leukemia with FLT3 mutation: background and design of the ADMIRAL trial.

Gorcea CM, Burthem J, Tholouli E.

Future Oncol. 2018 Aug;14(20):1995-2004. doi: 10.2217/fon-2017-0582. Epub 2018 Mar 2. Review.

PMID:
29498296
7.

Derepression of the Iroquois Homeodomain Transcription Factor Gene IRX3 Confers Differentiation Block in Acute Leukemia.

Somerville TDD, Simeoni F, Chadwick JA, Williams EL, Spencer GJ, Boros K, Wirth C, Tholouli E, Byers RJ, Somervaille TCP.

Cell Rep. 2018 Jan 16;22(3):638-652. doi: 10.1016/j.celrep.2017.12.063.

8.

In vivo T-depleted reduced-intensity transplantation for GATA2-related immune dysfunction.

Tholouli E, Sturgess K, Dickinson RE, Gennery A, Cant AJ, Jackson G, Lordan J, Hambleton S, Slatter MA, Bigley V, Collin M.

Blood. 2018 Mar 22;131(12):1383-1387. doi: 10.1182/blood-2017-10-811489. Epub 2018 Jan 2. No abstract available.

9.

UK consensus statement on the use of plerixafor to facilitate autologous peripheral blood stem cell collection to support high-dose chemoradiotherapy for patients with malignancy.

Douglas KW, Gilleece M, Hayden P, Hunter H, Johnson PRE, Kallmeyer C, Malladi RK, Paneesha S, Pawson R, Quinn M, Raj K, Richardson D, Robinson S, Russell N, Snowden J, Sureda A, Tholouli E, Thomson K, Watts M, Wilson KM.

J Clin Apher. 2018 Feb;33(1):46-59. doi: 10.1002/jca.21563. Epub 2017 Jun 20. Review.

PMID:
28631842
10.

Salvage use of allogeneic hematopoietic stem cell transplantation after reduced intensity conditioning from unrelated donors in multiple myeloma. A study by the Plasma Cell Disorders subcommittee of the European Group for Blood and Marrow Transplant Chronic Malignancies Working Party.

Sobh M, Michallet M, Dubois V, Iacobelli S, Koster L, Van Biezen A, Fegueux N, Tabrizi R, Finke J, El-Cheikh J, Schipperus M, Meijer E, von dem Borne P, Petersen E, Russell N, Tholouli E, Passweg J, Garban F, Maertens J, Chevalier P, Maillard N, Volin L, Francois S, Lioure B, Beguin Y, Gluckman E, Ruggeri A, Garderet L, Kröger N.

Haematologica. 2017 Jul;102(7):e271-e274. doi: 10.3324/haematol.2017.165399. Epub 2017 Apr 20. No abstract available.

11.

Effective use of oral ribavirin for respiratory syncytial viral infections in allogeneic haematopoietic stem cell transplant recipients.

Gorcea CM, Tholouli E, Turner A, Saif M, Davies E, Battersby E, Dignan FL.

J Hosp Infect. 2017 Feb;95(2):214-217. doi: 10.1016/j.jhin.2016.11.012. Epub 2016 Nov 25.

PMID:
28077243
12.

[Compassion as a mediator between stressful events and perceived stress in Greek students].

Tholouli E, Maridaki-Kassotaki A, Varvogli L, Chrousos GP.

Psychiatriki. 2016 Apr-Jun;27(2):89-97. Greek, Modern.

13.

Outcome of patients with chronic myeloid leukemia and a low-risk score: allogeneic hematopoietic stem cell transplantation in the era of targeted therapy. A report from the EBMT Chronic Malignancies Working Party.

Koenecke C, Heim D, van Biezen A, Heuser M, Aljurf M, Kyrcz-Krzemien S, Volin L, de Souza CA, Gedde-Dahl T, Sengeloev H, Schanz U, Komarnicki M, Arroyo CH, Tholouli E, Gluckman E, Esquirol A, Yakoub-Agha I, Gürman G, Olavarria E, Kröger N.

Bone Marrow Transplant. 2016 Sep;51(9):1259-61. doi: 10.1038/bmt.2016.97. Epub 2016 Apr 25. No abstract available.

PMID:
27111041
14.

Tolerability and Clinical Activity of Post-Transplantation Azacitidine in Patients Allografted for Acute Myeloid Leukemia Treated on the RICAZA Trial.

Craddock C, Jilani N, Siddique S, Yap C, Khan J, Nagra S, Ward J, Ferguson P, Hazlewood P, Buka R, Vyas P, Goodyear O, Tholouli E, Crawley C, Russell N, Byrne J, Malladi R, Snowden J, Dennis M.

Biol Blood Marrow Transplant. 2016 Feb;22(2):385-390. doi: 10.1016/j.bbmt.2015.09.004. Epub 2015 Sep 9.

15.

Increased SYK activity is associated with unfavorable outcome among patients with acute myeloid leukemia.

Boros K, Puissant A, Back M, Alexe G, Bassil CF, Sinha P, Tholouli E, Stegmaier K, Byers RJ, Rodig SJ.

Oncotarget. 2015 Sep 22;6(28):25575-87. doi: 10.18632/oncotarget.4669.

16.

A multicentre UK study of GVHD following DLI: rates of GVHD are high but mortality from GVHD is infrequent.

Scarisbrick JJ, Dignan FL, Tulpule S, Gupta ED, Kolade S, Shaw B, Evison F, Shah G, Tholouli E, Mufti G, Pagliuca A, Malladi R, Raj K.

Bone Marrow Transplant. 2015 Jan;50(1):62-7. doi: 10.1038/bmt.2014.227. Epub 2014 Oct 13.

PMID:
25310308
17.

Impact of pre-transplant co-morbidities on outcome after alemtuzumab-based reduced intensity conditioning allo-SCT in elderly patients: a British Society of Blood and Marrow Transplantation study.

Nikolousis E, Nagra S, Pearce R, Perry J, Kirkland K, Byrne J, Dignan F, Tholouli E, Gilleece M, Russell N, Littlewood T, Cook M, Peniket A, Shaw BE, Cook G, Craddock C.

Bone Marrow Transplant. 2015 Jan;50(1):82-6. doi: 10.1038/bmt.2014.215. Epub 2014 Oct 6.

PMID:
25285801
18.

Hematopoietic stem-cell transplantation for advanced systemic mastocytosis.

Ustun C, Reiter A, Scott BL, Nakamura R, Damaj G, Kreil S, Shanley R, Hogan WJ, Perales MA, Shore T, Baurmann H, Stuart R, Gruhn B, Doubek M, Hsu JW, Tholouli E, Gromke T, Godley LA, Pagano L, Gilman A, Wagner EM, Shwayder T, Bornhäuser M, Papadopoulos EB, Böhm A, Vercellotti G, Van Lint MT, Schmid C, Rabitsch W, Pullarkat V, Legrand F, Yakoub-Agha I, Saber W, Barrett J, Hermine O, Hagglund H, Sperr WR, Popat U, Alyea EP, Devine S, Deeg HJ, Weisdorf D, Akin C, Valent P.

J Clin Oncol. 2014 Oct 10;32(29):3264-74. doi: 10.1200/JCO.2014.55.2018. Epub 2014 Aug 25.

19.

The evolution of cellular deficiency in GATA2 mutation.

Dickinson RE, Milne P, Jardine L, Zandi S, Swierczek SI, McGovern N, Cookson S, Ferozepurwalla Z, Langridge A, Pagan S, Gennery A, Heiskanen-Kosma T, Hämäläinen S, Seppänen M, Helbert M, Tholouli E, Gambineri E, Reykdal S, Gottfreðsson M, Thaventhiran JE, Morris E, Hirschfield G, Richter AG, Jolles S, Bacon CM, Hambleton S, Haniffa M, Bryceson Y, Allen C, Prchal JT, Dick JE, Bigley V, Collin M.

Blood. 2014 Feb 6;123(6):863-74. doi: 10.1182/blood-2013-07-517151. Epub 2013 Dec 17.

20.

Quantitative multiplex quantum dot in-situ hybridisation based gene expression profiling in tissue microarrays identifies prognostic genes in acute myeloid leukaemia.

Tholouli E, MacDermott S, Hoyland J, Yin JL, Byers R.

Biochem Biophys Res Commun. 2012 Aug 24;425(2):333-9. doi: 10.1016/j.bbrc.2012.07.092. Epub 2012 Jul 25.

PMID:
22842570
21.

Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia.

Kentsis A, Reed C, Rice KL, Sanda T, Rodig SJ, Tholouli E, Christie A, Valk PJ, Delwel R, Ngo V, Kutok JL, Dahlberg SE, Moreau LA, Byers RJ, Christensen JG, Vande Woude G, Licht JD, Kung AL, Staudt LM, Look AT.

Nat Med. 2012 Jul;18(7):1118-22. doi: 10.1038/nm.2819.

22.

Detection of IDH1 R132H mutation in acute myeloid leukemia by mutation-specific immunohistochemistry.

Byers R, Hornick JL, Tholouli E, Kutok J, Rodig SJ.

Appl Immunohistochem Mol Morphol. 2012 Jan;20(1):37-40. doi: 10.1097/PAI.0b013e31822c132e.

PMID:
22172803
23.

MSI2 protein expression predicts unfavorable outcome in acute myeloid leukemia.

Byers RJ, Currie T, Tholouli E, Rodig SJ, Kutok JL.

Blood. 2011 Sep 8;118(10):2857-67. doi: 10.1182/blood-2011-04-346767. Epub 2011 Jul 13.

PMID:
21753187
24.

The clinical management of tumour lysis syndrome in haematological malignancies.

Will A, Tholouli E.

Br J Haematol. 2011 Jul;154(1):3-13. doi: 10.1111/j.1365-2141.2011.08697.x. Epub 2011 May 9. Review.

PMID:
21554259
25.

Factors predicting long-term survival after T-cell depleted reduced intensity allogeneic stem cell transplantation for acute myeloid leukemia.

Craddock C, Nagra S, Peniket A, Brookes C, Buckley L, Nikolousis E, Duncan N, Tauro S, Yin J, Liakopoulou E, Kottaridis P, Snowden J, Milligan D, Cook G, Tholouli E, Littlewood T, Peggs K, Vyas P, Clark F, Cook M, Mackinnon S, Russell N.

Haematologica. 2010 Jun;95(6):989-95. doi: 10.3324/haematol.2009.013920. Epub 2009 Nov 30.

26.

Stage IV adult sporadic Burkitt lymphoma/leukemia with complex bone marrow cytogenetics is associated with a very poor outcome.

Tholouli E, Watt S, Lucas GS, Burthem J, Yin JA, Cavet J, Greenfield H, Houghton JB.

Blood. 2009 Jul 9;114(2):485-6; author reply 486-7. doi: 10.1182/blood-2009-03-213231. No abstract available.

PMID:
19589933
27.

Orthodontic treatment for a patient who developed acute myeloid leukemia.

Isaac AM, Tholouli E.

Am J Orthod Dentofacial Orthop. 2008 Nov;134(5):684-8. doi: 10.1016/j.ajodo.2006.10.024.

PMID:
18984402
28.

Quantum dots light up pathology.

Tholouli E, Sweeney E, Barrow E, Clay V, Hoyland JA, Byers RJ.

J Pathol. 2008 Nov;216(3):275-85. doi: 10.1002/path.2421. Review.

PMID:
18814189
29.

Outcomes following 50 mg versus 100 mg alemtuzumab in reduced-intensity conditioning stem cell transplants for acute myeloid leukaemia and poor risk myelodysplasia.

Tholouli E, Liakopoulou E, Greenfield HM, Shaw BE, Tauro S, Byrne JL, Dennis M, Burthem J, Lucas GS, Craddock C, Russell NH, Liu Yin JA.

Br J Haematol. 2008 Jun;142(2):318-20. doi: 10.1111/j.1365-2141.2008.07184.x. Epub 2008 May 19. No abstract available.

PMID:
18492100
30.

Semiautomated multiplexed quantum dot-based in situ hybridization and spectral deconvolution.

Byers RJ, Di Vizio D, O'connell F, Tholouli E, Levenson RM, Gossage K, Twomey D, Yang Y, Benedettini E, Rose J, Ligon KL, Finn SP, Golub TR, Loda M.

J Mol Diagn. 2007 Feb;9(1):20-9. Erratum in: J Mol Diagn. 2007 Sep;9(4):561. Gossard, Kirk [corrected to Gossage, Kirk].

31.
32.

Imaging of multiple mRNA targets using quantum dot based in situ hybridization and spectral deconvolution in clinical biopsies.

Tholouli E, Hoyland JA, Di Vizio D, O'Connell F, Macdermott SA, Twomey D, Levenson R, Yin JA, Golub TR, Loda M, Byers R.

Biochem Biophys Res Commun. 2006 Sep 22;348(2):628-36. Epub 2006 Jul 31.

PMID:
16893519
33.

Comparison of gene-expression profiles in parallel bone marrow and peripheral blood samples in acute myeloid leukaemia by real-time polymerase chain reaction.

Sakhinia E, Farahangpour M, Tholouli E, Liu Yin JA, Hoyland JA, Byers RJ.

J Clin Pathol. 2006 Oct;59(10):1059-65. Epub 2006 Apr 27.

34.

Crystal-storing histiocytosis in a patient with IgG kappa multiple myeloma.

Tholouli E, Krebs M, Reeve R, Houghton JB.

Br J Haematol. 2005 Feb;128(4):412. No abstract available.

PMID:
15686450
35.

Acquired Glanzmann's thrombasthenia without thrombocytopenia: a severe acquired autoimmune bleeding disorder.

Tholouli E, Hay CR, O'Gorman P, Makris M.

Br J Haematol. 2004 Oct;127(2):209-13. Review.

PMID:
15461628
36.

Littoral cell angioma of the spleen in a patient with severe aplastic anaemia.

Tholouli E, Roulson JA, Byers R, Burton I, Liu Yin JA.

Haematologica. 2003 Nov;88(11):ECR33.

37.

Littoral cell angioma of the spleen in a patient with severe aplastic anaemia.

Tholouli E, Roulson JA, Byers R, Burton I, Liu Yin JA.

Haematologica. 2003 Sep;88(9):ECR30.

Supplemental Content

Loading ...
Support Center